FR2275225A1 - Nouveau medicament pour corriger les troubles de l'equilibre hydro-electrolytique provoques par une secretion excessive ou inappropriee d'hormone antidiuretique - Google Patents
Nouveau medicament pour corriger les troubles de l'equilibre hydro-electrolytique provoques par une secretion excessive ou inappropriee d'hormone antidiuretiqueInfo
- Publication number
- FR2275225A1 FR2275225A1 FR7421447A FR7421447A FR2275225A1 FR 2275225 A1 FR2275225 A1 FR 2275225A1 FR 7421447 A FR7421447 A FR 7421447A FR 7421447 A FR7421447 A FR 7421447A FR 2275225 A1 FR2275225 A1 FR 2275225A1
- Authority
- FR
- France
- Prior art keywords
- vasopressin
- compsns
- excess
- metabolic disorders
- compns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010004977 Vasopressins Proteins 0.000 title abstract 6
- 102000002852 Vasopressins Human genes 0.000 title abstract 6
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title abstract 5
- 229960003726 vasopressin Drugs 0.000 title abstract 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title abstract 2
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract 2
- 239000002170 aldosterone antagonist Substances 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940116211 Vasopressin antagonist Drugs 0.000 title 1
- 239000003038 vasopressin antagonist Substances 0.000 title 1
- JLTCWSBVQSZVLT-UHFFFAOYSA-N n-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxa Chemical compound NCCCCC(C(=O)NCC(N)=O)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 JLTCWSBVQSZVLT-UHFFFAOYSA-N 0.000 abstract 2
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 abstract 1
- 101800001144 Arg-vasopressin Proteins 0.000 abstract 1
- 108010048179 Lypressin Proteins 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
- 230000002686 anti-diuretic effect Effects 0.000 abstract 1
- 229940124538 antidiuretic agent Drugs 0.000 abstract 1
- 239000003160 antidiuretic agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 229960003837 lypressin Drugs 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
- 229960002256 spironolactone Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7421447A FR2275225A1 (fr) | 1974-06-20 | 1974-06-20 | Nouveau medicament pour corriger les troubles de l'equilibre hydro-electrolytique provoques par une secretion excessive ou inappropriee d'hormone antidiuretique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7421447A FR2275225A1 (fr) | 1974-06-20 | 1974-06-20 | Nouveau medicament pour corriger les troubles de l'equilibre hydro-electrolytique provoques par une secretion excessive ou inappropriee d'hormone antidiuretique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2275225A1 true FR2275225A1 (fr) | 1976-01-16 |
| FR2275225B1 FR2275225B1 (enExample) | 1978-07-21 |
Family
ID=9140302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7421447A Granted FR2275225A1 (fr) | 1974-06-20 | 1974-06-20 | Nouveau medicament pour corriger les troubles de l'equilibre hydro-electrolytique provoques par une secretion excessive ou inappropriee d'hormone antidiuretique |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2275225A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1031352A3 (en) * | 1999-02-23 | 2001-12-05 | Universidad Nacional de Quilmes | Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery |
-
1974
- 1974-06-20 FR FR7421447A patent/FR2275225A1/fr active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1031352A3 (en) * | 1999-02-23 | 2001-12-05 | Universidad Nacional de Quilmes | Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2275225B1 (enExample) | 1978-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK120337B (da) | Fremgangsmåde til fremstilling af terapeutisk aktive 3-keto-6-halogen-9β10α-Δ<4,6>-steroiddiener af androstan- eller pregnanrækken. | |
| AU473594B2 (en) | Anaesthetic steroids ofthe pregnane series | |
| IL32901A0 (en) | Glycosidyl and clycuronosidyl steroids of the estrane series,preparation thereof and use as estrogenic agents | |
| IL36654A0 (en) | New oestrogenically highly active steroids of the estrane series,their manufacture and pharmaceutical compositions containing them | |
| IL38241A (en) | 6alpha,16alpha-dimethyl-21-hydroxy-delta1,4-pregnadiene-3,20-diones | |
| CA614881A (en) | Base sack anchoring means | |
| IL25294A (en) | Preparation of 6alpha,9alpha-difluoro-16-methylene-1,4-pregnadiene-11beta,17alpha-diol-3,20-dione and 17alpha-ol-3,11,20-trione | |
| CA700249A (en) | 16.alpha.,17.alpha.-SUBSTITUTED METHYLENE DIOXY ETHERS OF STEROIDS OF THE PREGNANE SERIES AND METHOD OF PREPARING THE SAME | |
| IL35598A (en) | The manufacture of 4,6-dichloro-16-methylene-17alpha-hydroxy-pregna-4,6-diene-3,20-dione and the new 4,6-dichloro-16beta-chloromethyl-16alpha,17alpha-epoxy-pregna-4,6-diene-3,20dione | |
| CA649017A (en) | Fertilizer mixing and spreading machine | |
| FI793027A7 (fi) | Uusia androstaani-, estraani- ja pregnaani-sarjan 3 -amino-2 -hydroksi-steroideja, menetelmiä niiden vavalmistamiseksi sekä farmaseuttisia yhdistelmiä. | |
| CA743940A (en) | Fluorination of .delta.2 or .delta.5 steroids of the androstane, pregnane and cholestane series with nitro-sylfluoride | |
| AT272536B (de) | Verfahren zur Herstellung von Androsta-1,4-dien-3,17-dion | |
| CA750366A (en) | .delta.2,4 steroid compounds of the androstane and pregnane series | |
| GB1133553A (en) | Inhalation aerosol composition | |
| IL30492A (en) | 3-hydroxy-4,6-dihalo-steroids of the pregnane and androstane series,their manufacture and pharmaceutical compositions containing them | |
| AKEY et al. | Radio blackout alleviation and plasma diagnostic results from a 25000 foot per second blunt-body reentry(Radio blackout alleviation and plasma diagnostic results from 25000 foot per second blunt body reentry) | |
| CA618643A (en) | Method and apparatus for making electron discharge devices having luminescent screens | |
| CA532771A (en) | Anchoring devices for lading ties and the like | |
| CA635208A (en) | Apparatus for dosing, mixing and applying | |
| IL36652A0 (en) | A new oestrogenically highly active steroid of the estrane series,its manufacture and pharmaceutical compositions containing it | |
| CA594678A (en) | 3,11-diketo steroids of the pregnane series | |
| IE32101B1 (en) | 4,6-dichloro-delta4,6-steroids of the pregnane and androstane series | |
| IL25048A (en) | 6-halomethyl-3-oxo-4,6-dienic steroids of the androstane,19-nor-androstane and pregnane series and process for the manufacture thereof | |
| CA718007A (en) | 4,4,14-trimethyl steroids of the pregnane series |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |